Identification of new Wilms tumour predisposition genes: an exome sequencing study. (May 2019)

• Record Type: Journal Article
• Authors: Mahamdallie, Shazia; Yost, Shawn; Poyastro-Pearson, Emma; Holt, Esty; Zachariou, Anna; Seal, Sheila; Elliott, Anna; Clarke, Matthew; Warren-Perry, Margaret; Hanks, Sandra; Anderson, John; Bomken, Simon; Cole, Trevor; Farah, Roula; Furtwaengler, Rhoikos; Glaser, Adam; Grundy, Richard; Hayden, James; Lowis, Steve; Millot, Frédéric; Nicholson, James; Ronghe, Milind; Skeen, Jane; Williams, Denise; Yeomanson, Daniel; Ruark, Elise; Rahman, Nazneen
• Is Part Of: Lancet. Volume 3:Number 5(2019)
• Page Start: 322
• Page End: 331
• Publication Date: 2019-05
• Subjects: Pediatrics -- Periodicals; Children -- Health and hygiene -- Periodicals; Adolescent medicine -- Periodicals; Teenagers -- Health and hygiene -- Periodicals; 618.920005
• DOI: 10.1016/S2352-4642(19)30018-5
• Languages: English
• ISSNs: 2352-4642

Abstract

Summary: Background: Wilms tumour is the most common childhood renal cancer and is genetically heterogeneous. While several Wilms tumour predisposition genes have been identified, there is strong evidence that further predisposition genes are likely to exist. Our study aim was to identify new predisposition genes for Wilms tumour. Methods: In this exome sequencing study, we analysed lymphocyte DNA from 890 individuals with Wilms tumour, including 91 affected individuals from 49 familial Wilms tumour pedigrees. We used the protein-truncating variant prioritisation method to prioritise potential disease-associated genes for further assessment. We evaluated new predisposition genes in exome sequencing data that we generated in 334 individuals with 27 other childhood cancers and in exome data from The Cancer Genome Atlas obtained from 7632 individuals with 28 adult cancers. Findings: We identified constitutional cancer-predisposing mutations in 33 individuals with childhood cancer. The three identified genes with the strongest signal in the protein-truncating variant prioritisation analyses were TRIM28, FBXW7, and NYNRIN . 21 of 33 individuals had a mutation in TRIM28 ; there was a strong parent-of-origin effect, with all ten inherited mutations being maternally transmitted (p=0·00098). We also found a strong association with the rare epithelial subtype of Wilms tumour, with 14 of 16 tumours being epithelial or epithelial predominant. There were no TRIM28 mutations in individuals with other childhood or adult cancers. We identified truncating FBXW7 mutations in four individuals with Wilms tumour and a de-novo non-synonymous FBXW7 mutation in a child with a rhabdoid tumour. Biallelic truncating mutations in NYNRIN were identified in three individuals with Wilms tumour, which is highly unlikely to have occurred by chance (p<0·0001). Finally, we identified two de-novo KDM3B mutations, supporting the role of KDM3B as a childhood cancer predisposition gene. Interpretation: The four new Wilms tumour predisposition genes identified— TRIM28, FBXW7, NYNRIN, and KDM3B —are involved in diverse biological processes and, together with the other 17 known Wilms tumour predisposition genes, account for about 10% of Wilms tumour cases. The overlap between these 21 constitutionally mutated predisposition genes and 20 genes somatically mutated in Wilms tumour is limited, consisting of only four genes. We recommend that all individuals with Wilms tumour should be offered genetic testing and particularly, those with epithelial Wilms tumour should be offered TRIM28 genetic testing. Only a third of the familial Wilms tumour clusters we analysed were attributable to known genes, indicating that further Wilms tumour predisposition factors await discovery. Funding: Wellcome Trust.